Any feedback?
Literature summary for 6.3.2.2 extracted from
- Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of gamma-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells (2009), Cancer Chemother. Pharmacol., 64, 715-721.
Application
| Application | Comment | Organism |
|---|---|---|
| pharmacology | co-treatment by indomethacin and doxorubicin increases the cytotoxicitiy of doxorubicin by decreasing the intracellular contents of glutathione and its conjugates with decreasing expression of gamma-glutamylcysteine synthetase. Indomethacin inhibits the gamma-glutamylcysteine synthetase promoter activity. | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
activity of the gamma-glutamylcysteine synthetase promoter decreases after indomethacin treatment | - |
| Homo sapiens | - |
leukemia cell. Cells show increased expression of gamma-glutamylcysteine synthetase. Expression decreases by indomethacin treatment | - |
Expression
| Organism | Comment | Expression |
|---|---|---|
| Homo sapiens | indomethacin inhibits the gamma-glutamylcysteine synthetase promoter activity. Co-treatment by indomethacin and doxorubicin increases the cytotoxicitiy of doxorubicin by decreasing the intracellular contents of glutathione and its conjugates with decreasing expression of gamma-glutamylcysteine synthetase | down |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
